Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Stroke. 2012 May 8;43(7):1925–1930. doi: 10.1161/STROKEAHA.111.647982

Figure 5.

Figure 5

Bevacizumab treatment reduced vessel density and dysplasia in the adult mouse bAVM model. (A) Representative images show lectin-stained vessels. There are fewer irregular shaped large vessels (arrows) in the bevacizumab treated group as compared to trastuzumab. Scale bar: 50 μm. (B) Bar graph shows quantification of vessel density and dysplasia index. Bevacizumab treatment reduced vessel density (*p=0.01) and dysplasia index (*p=0.02) as compared to trastuzumab treatment.